Cargando…

Osteonectin as a screening marker for pancreatic cancer: A prospective study

OBJECTIVE: Osteonectin plays a central role in various processes during the development of pancreatic adenocarcinoma. This prospective pilot study was performed to determine the feasibility of serum osteonectin as a screening tool for pancreatic cancer. METHODS: Blood samples were collected from 15...

Descripción completa

Detalles Bibliográficos
Autores principales: Papapanagiotou, Angeliki, Sgourakis, George, Karkoulias, Kyriakos, Raptis, Dimitris, Parkin, Edward, Brotzakis, Pantelis, Panchal, Sanjay, Papavassiliou, Athanasios G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6124255/
https://www.ncbi.nlm.nih.gov/pubmed/29756486
http://dx.doi.org/10.1177/0300060518772413
Descripción
Sumario:OBJECTIVE: Osteonectin plays a central role in various processes during the development of pancreatic adenocarcinoma. This prospective pilot study was performed to determine the feasibility of serum osteonectin as a screening tool for pancreatic cancer. METHODS: Blood samples were collected from 15 consecutive patients with newly diagnosed pancreatic cancer and 30 matched healthy controls. Serum osteonectin was measured using an osteonectin enzyme-linked immunosorbent assay kit. The primary outcomes were the diagnostic performance of serum osteonectin and the threshold value for differentiation of patients from controls. RESULTS: The median/quartile range of serum osteonectin in patients and controls were 306.8/288.5 ng/mL and 67.5/39.8 ng/mL, respectively. Osteonectin concentrations significantly differed among the study groups. A plasma osteonectin concentration of >100.18 ng/mL as selected by the receiver operating characteristic curves demonstrated an estimated area under the curve of 86% for prediction of pancreatic cancer. Tumour size was a significant predictor of serum osteonectin. A statistically significant difference in serum osteonectin between T1/T2 and T3/T4 tumours was found. Post-hoc comparisons revealed statistically significant differences in the serum osteonectin among the control, T1/T2, and T3/T4 groups. CONCLUSION: Osteonectin may be used as a screening tool for pancreatic cancer, although this must be validated in prospective studies.